ANG1005

ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system[1][2][3].

Product Specifications

CAS Number

[1075214-55-9]

Product Name Alternative

GRN1005; Paclitaxel trevatide

UNSPSC

12352209

Target

LDLR; Peptide-Drug Conjugates (PDCs)

Type

Peptides

Related Pathways

Antibody-drug Conjugate/ADC Related; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ang1005.html

Purity

98.83

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C([C@@H](NC(CCC(O[C@H]([C@H](C1=CC=CC=C1)NC(C2=CC=CC=C2)=O)C(O[C@@H]3C(C)=C([C@H](C([C@]4(C)[C@H](C[C@@]([H])(OC5)[C@]5(OC(C)=O)[C@]4([C@@H]([C@@]6(C3)O)OC(C7=CC=CC=C7)=O)[H])O)=O)OC(C)=O)C6(C)C)=O)=O)=O)[C@@H](C)O)N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CC8=CC=C(O)C=C8)=O)CCC(O)=O)=O)CCC(O)=O)=O)[C@@H](C)O)=O)CCCCNC(CCC(O[C@H]([C@H](C9=CC=CC=C9)NC(C%10=CC=CC=C%10)=O)C(O[C@@H]%11C(C)=C([C@H](C([C@]%12(C)[C@H](C[C@@]([H])(OC%13)[C@]%13(OC(C)=O)[C@]%12([C@@H]([C@@]%14(C%11)O)OC(C%15=CC=CC=C%15)=O)[H])O)=O)OC(C)=O)C%14(C)C)=O)=O)=O)=O)CC%16=CC=CC=C%16)=O)CC(N)=O)=O)CC(N)=O)=O)CCCNC(N)=N)=O)CCCCNC(CCC(O[C@H]([C@H](C%17=CC=CC=C%17)NC(C%18=CC=CC=C%18)=O)C(O[C@@H]%19C(C)=C([C@H](C([C@]%20(C)[C@H](C[C@@]([H])(OC%21)[C@]%21(OC(C)=O)[C@]%20([C@@H]([C@@]%22(C%19)O)OC(C%23=CC=CC=C%23)=O)[H])O)=O)OC(C)=O)C%22(C)C)=O)=O)=O)=O)=O)CCCNC(N)=N)=O)CO)=O)=O)=O)CC%24=CC=C(O)C=C%24)=O)CC%25=CC=CC=C%25)=O)CC%26=CC=CC=C%26

Molecular Formula

C257H308N32O79

Molecular Weight

5109.36

References & Citations

[1]Thomas FC, et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res. 2009 Nov;26 (11) :2486-94.|[2]Li F, et al. Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB) . Genes Dis. 2017 Feb 10;4 (1) :1-3.|[3]Kumthekar P, et al. ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020 Jun 15;26 (12) :2789-2799.